New vaccine combo aims to halt early myeloma
NCT ID NCT02886065
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a cancer vaccine (PVX-410) combined with two drugs (citarinostat and lenalidomide) in 19 people with smoldering multiple myeloma, a pre-cancer condition. The goal is to see if the combination is safe and can trigger an immune response against myeloma cells. Researchers will also monitor changes in blood markers to look for signs of disease control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PVX-410 (cancer vaccine), citarinostat, lenalidomide, and Hiltonol
What this could lead to
If successful, this combination could help control smoldering multiple myeloma and delay or prevent progression to active disease.
What could go wrong
This is a very early phase 1 trial with only 19 participants, focused on safety. The vaccine and drugs may not produce strong immune responses or clinical benefit, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University Hospital of Cleveland- Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States